New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:12 EDTADMSAdamas Pharmaceuticals initiated with an Outperform at William Blair
News For ADMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
06:05 EDTADMSAdamas Pharmaceuticals files to sell $150M in common stock, 1.6M for holders
Subscribe for More Information
May 13, 2015
16:39 EDTADMSAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
16:03 EDTADMSAdamas Pharmaceuticals reports Q1 EPS (69c), consensus (74c)
Reports Q1 revenue $226,000 vs. $176,000 last year. Reports $145M in cash, cash equivalents, and marketable securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use